Abstract
SummaryIncreasing the capacity of the immune system to mediate tumour regression has been a major goal in tumour immunology. Progress towards this goal has been recently aided by the identification of immunogenic cancer antigens and by a better understanding of the mechanisms of T-cell immune response and tumour escape. A rare antigen-presenting cell -the dendritic cell (DC) - appears to be the key to these mechanisms. The passibilitgr of generating these cells in vitro from blood precursors has initiated a new era in cancer immunotherapy. Using DC as a cancer vaccine adjuvant has led to reports of measurable immune responses, and, in a few cases, to complete disease responses in patients with B-cell lymphoma and melanoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
